ERK1/2 is a mitogen-activated protein kinase (MAPK) signaling pathway activated in heart failure. Protection against heart failure can be achieved by inhibiting the signaling pathway with therapeutic nanoparticle composed of PD98059 and PLGA to reverse the negative outcome of SNA changes. We propose that drug loaded particles containing PD98059 and PLGA (acting as a ligand) can be used to target this pathway and reverse negative outcomes of heart failure. PLGA is incorporated as a ligand because it decomposes without induction of inflammation or immune reaction. To improve the likelihood of these drug loaded particle crossing the blood-brain-barrier, optimizing the particle preparation method to acquire particle size distribution below 200nm is required. Also, obtaining particles with a positive surface charge is important. We will use sonication to prepare a nanoparticles formulation mixture and a lyophilizer to freeze dry the particles to aid in changing this formulation into dry powder. In addition, we will apply a PEG linker to change the surface charge. To determine if the criteria’s are met, a scanning electron microscopy will be incorporated to take pictures of these particles, a dynamic light scattering (DLS) will be used to analyze the particle size distribution and the Zeta potential analysis was used to analyze that surface charge of each particle in solution.  We expect that when these particles are tested in rats, they will reduce the symptoms of heart failure because they meet all the necessary criteria to penetrate the blood brain barrier.